How Does the Tumor Exploit Stress Signals?
July 10, 2026Core Framework & Diagram Future Directions in Tumor Immunology
July 14, 2026
Future Directions in Tumor Immunology
Your stress is helping the tumor grow — this is not a metaphor, this is molecular biology
By the Editors 1-min read
In 2010, immune checkpoint inhibitors transformed melanoma treatment. In 2022, personalized mRNA tumor vaccines were proven effective in Phase III trials. In 2024, CD19 CAR-T achieved 'functional cure' in autoimmune disease. Tumor immunology is evolving at unprecedented speed.
This is the closing article of the entire tumor immunology foundations section — also a map looking forward. Not science fiction, but based on currently ongoing clinical trials and the most important scientific discoveries in recent years, surveying the most important directions in tumor immunology over the next ten to fifteen years.
Understanding these directions isn't only about knowing 'what treatments will look like' — it's understanding 'what problems today's science is trying to solve.' That's the key to transforming all this knowledge from information into genuine understanding.
KEY TAKEAWAYS
01
Bispecific antibodies 'force a handshake' bypassing DC activation to directly guide circulating T cells to tumor sites, solving the T cell absence problem in 'cold tumors.' Blinatumomab has proven clinical value in B-ALL; the specificity target problem for solid tumor bispecifics is the current biggest challenge.
02
Next-generation CAR-T's three breakthrough directions: neoantigen-targeting high-specificity CAR-T; Armored CAR-T (self-producing cytokines to overcome TME metabolic deprivation and exhaustion); universal off-the-shelf allogeneic CAR-T (CRISPR editing, shortened preparation time, reduced cost).
03
AI is reshaping tumor immunology from three dimensions: AlphaFold and similar protein structure prediction compresses neoantigen screening from weeks to hours; generative AI de novo designs TCR and antibodies; multimodal AI predicts immunotherapy response with precision exceeding single biomarkers.
04
Cancer preventive vaccines are moving from 'concept' to 'clinical trials': KRAS G12D preventive vaccine for IPMN high-risk populations; Lynch syndrome shared neoantigen vaccines for colorectal cancer ultra-high-risk populations — representing the historic shift in cancer prevention from 'treatment' to 'prevention.'
05
'Functional cure' is the most reasonable target for 2035: not necessarily complete elimination of all cancer cells, but immune system maintaining persistent 'symptom-free equilibrium.' High-TMB solid tumors and blood tumors have the best chance of being first; low-TMB solid tumors (pancreatic cancer, glioblastoma) remain the hardest unsolved challenge.
Art 81
How Does Sleep Affect Immunity?
→
Art 82
How Does Stress Affect Immunity?
→
